Literature DB >> 12365204

Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.

Ene I Ette1, Leonard C Onyiah.   

Abstract

A simulation study was performed to determine how inestimable standard errors could be obtained when population pharmacokinetic analysis is performed with the NONMEM software on data from small sample size phase I studies. Plausible sets of concentration-time data for nineteen subjects were simulated using an incomplete longitudinal population pharmacokinetic study design, and parameters of a drug in development that exhibits two compartment linear pharmacokinetics with single dose first order input. They were analyzed with the NONMEM program. Standard errors for model parameters were computed from the simulated parameter values to serve as true standard errors of estimates. The nonparametric bootstrap approach was used to generate replicate data sets from the simulated data and analyzed with NONMEM. Because of the sensitivity of the bootstrap to extreme values, winsorization was applied to parameter estimates. Winsorized mean parameters and their standard errors were computed and compared with their true values as well as the non-winsorized estimates. Percent bias was used to judge the performance of the bootstrap approach (with or without winsorization) in estimating inestimable standard errors of population pharmacokinetic parameters. Winsorized standard error estimates were generally more accurate than non-winsorized estimates because the distribution of most parameter estimates were skewed, sometimes with heavy tails. Using the bootstrap approach combined with winsorization, inestimable robust standard errors can be obtained for NONMEM estimated population pharmacokinetic parameters with > or = 150 bootstrap replicates. This approach was also applied to a real data set and a similar outcome was obtained. This investigation provides a structural framework for estimating inestimable standard errors when NONMEM is used for population pharmacokinetic modeling involving small sample sizes.

Mesh:

Year:  2002        PMID: 12365204     DOI: 10.1007/BF03190460

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  The process of knowledge discovery from large pharmacokinetic data sets.

Authors:  E I Ette; P Williams; E Fadiran; F O Ajayi; L C Onyiah
Journal:  J Clin Pharmacol       Date:  2001-01       Impact factor: 3.126

2.  Designing population pharmacokinetic studies: performance of mixed designs.

Authors:  E O Fadiran; C D Jones; E I Ette
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

3.  Biometrical evaluation of bioequivalence trials using a bootstrap individual direct curve comparison method.

Authors:  E Zintzaras; P Bouka; A Kowald
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

4.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

5.  Mixed-effects nonlinear regression for unbalanced repeated measures.

Authors:  E F Vonesh; R L Carter
Journal:  Biometrics       Date:  1992-03       Impact factor: 2.571

6.  Estimating impossible curves using NONMEM.

Authors:  R C Schoemaker; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1996-09       Impact factor: 4.335

7.  Stability and performance of a population pharmacokinetic model.

Authors:  E I Ette
Journal:  J Clin Pharmacol       Date:  1997-06       Impact factor: 3.126

8.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

9.  Comparing non-hierarchical models: application to non-linear mixed effects modeling.

Authors:  E I Ette
Journal:  Comput Biol Med       Date:  1996-11       Impact factor: 4.589

10.  Population pharmacokinetic modeling: the importance of informative graphics.

Authors:  E I Ette; T M Ludden
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

  10 in total
  15 in total

1.  Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients.

Authors:  William Knebel; Mary Corcoran; James Ermer; Marc R Gastonguay
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

2.  Data supplementation: a pharmacokinetic/pharmacodynamic knowledge creation approach for characterizing an unexplored region of the response surface.

Authors:  Ene I Ette; Hui-May Chu; Christopher J Godfrey
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

3.  A random sampling approach for robust estimation of tissue-to-plasma ratio from extremely sparse data.

Authors:  Hui-May Chu; Ene I Ette
Journal:  AAPS J       Date:  2005-09-02       Impact factor: 4.009

4.  Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.

Authors:  Hoai-Thu Thai; France Mentré; Nicholas H G Holford; Christine Veyrat-Follet; Emmanuelle Comets
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-12-08       Impact factor: 2.745

5.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

6.  Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.

Authors:  Gabriel J Robbie; Liang Zhao; John Mondick; Genevieve Losonsky; Lorin K Roskos
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

7.  Population pharmacokinetic/pharmacodynamic modeling of guanfacine effects on QTc and heart rate in pediatric patients.

Authors:  William Knebel; James Ermer; Jaideep Purkayastha; Patrick Martin; Marc R Gastonguay
Journal:  AAPS J       Date:  2014-08-19       Impact factor: 4.009

8.  Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers.

Authors:  Carol Cronenberger; Diane R Mould; Hans-Juergen Roethig; Mohamadi Sarkar
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

9.  Population pharmacokinetics and optimal design of paediatric studies for famciclovir.

Authors:  Kayode Ogungbenro; Ivan Matthews; Michael Looby; Guenther Kaiser; Gordon Graham; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

10.  Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months.

Authors:  John T Mondick; Brendan M Johnson; Lynda J Haberer; Mark E Sale; Peter C Adamson; Charles J Coté; James M Croop; Mark W Russo; Jeffrey S Barrett; J Frank Hoke
Journal:  Eur J Clin Pharmacol       Date:  2009-10-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.